Immune checkpoint inhibitors (ICIs) are group of monoclonal antibodies targeting immune checkpoints including PD-1/PD-L1 and CTLA-4 etc. By blocking the interaction between immune checkpoints and their partners, ICIs mediate tumor killing effects through unleashing the “breaks” of immune system (3). This evidence concerns the gene CD274 and neoplasm.